First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

First Turn Management LLC lessened its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 325,218 shares of the biopharmaceutical company's stock after selling 14,658 shares during the period. First Turn Management LLC owned 0.43% of Xenon Pharmaceuticals worth $12,804,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in XENE. BNP Paribas Financial Markets increased its holdings in Xenon Pharmaceuticals by 89.5% in the first quarter. BNP Paribas Financial Markets now owns 8,321 shares of the biopharmaceutical company's stock valued at $358,000 after purchasing an additional 3,931 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Xenon Pharmaceuticals by 12.0% in the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company's stock valued at $228,000 after acquiring an additional 565 shares during the period. Vanguard Group Inc. boosted its stake in Xenon Pharmaceuticals by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 335,635 shares of the biopharmaceutical company's stock worth $14,449,000 after acquiring an additional 12,140 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Xenon Pharmaceuticals by 87.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 10,032 shares of the biopharmaceutical company's stock worth $432,000 after acquiring an additional 4,691 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new stake in Xenon Pharmaceuticals in the first quarter valued at approximately $195,000. Institutional investors own 95.45% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on XENE. HC Wainwright reissued a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. William Blair raised Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Raymond James reiterated an "outperform" rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $57.45.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock traded up $0.54 during mid-day trading on Tuesday, reaching $38.85. The company's stock had a trading volume of 434,805 shares, compared to its average volume of 389,580. Xenon Pharmaceuticals Inc. has a 12 month low of $28.20 and a 12 month high of $50.99. The business's 50 day simple moving average is $41.20 and its 200 day simple moving average is $40.29. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -13.59 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the firm posted ($0.73) earnings per share. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.